Home＞REGULATORY
3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing(May.17.2017)
FPMAJ Chairman Masayo Tada (left), JPMA President Yoshihiko Hatanaka |
Three major pharma trade groups of Japan, the US, and Europe all pressed for a scheme to keep NHI drug prices for the duration of the patent term at a hearing of a key drug pricing panel on May 17 - aiming to turn the tide amid a growing headwind for the so-called price maintenance premium ...
(LOG IN FOR FULL STORY)
-
Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May.19
-
JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May.19
-
JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May.19
-
FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May.18
-
(Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May.18
-
Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May.17
-
Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May.17
-
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
-
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Apr.17
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
